Dompé and The FarmaMondo Group Enter Agreement to Distribute Oxervate in Russia and Other CIS Countries

Dompé and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner to make Oxervate (cenegermin) available for patients with neurotrophic keratitis (NK) in Russia and other CIS countries.

Terms of the deal were not disclosed.

The agreement appoints FarmaMondo as the exclusive provider of access for those NK patients with unmet need through a Named Patient Managed Access Program.

“We are pleased to be working with FarmaMondo to deliver this innovative treatment to patients with a serious unmet medical need. We believe expanding the distribution of Oxervate will dramatically improve the life of many now living with a highly debilitating disease,” Eriona Gjinukaj, Chief Operating Officer of Dompé, said in a company news release.